Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2020 09:13 ET | Source: Junshi Biosciences

Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

SHANGHAI and INDIANAPOLIS, May 04, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop...
April 30, 2020 10:56 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma

SHANGHAI, China, April 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
March 30, 2020 21:29 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Approval of Proposed A-Share Listing by the Listing Committee for the Shanghai Stock Exchange (SSE) STAR Market

SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
March 30, 2020 12:43 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Full-Year 2019 Financial Results and Business Updates

SHANGHAI, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of...
March 30, 2020 12:30 ET | Source: Junshi Biosciences

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab in Combination with Pfizer’s Axitinib for the Treatment of Mucosal Melanoma

SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) today announced that the U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation...
March 20, 2020 12:15 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Co-Development Agreement with IMCAS to Advance Neutralizing Antibodies as Potential Novel Treatment for COVID-19

SHANGHAI, China, March 20, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) announced that it has recently signed a collaboration agreement with the Institute of Microbiology of the Chinese...
March 02, 2020 14:19 ET | Source: Junshi Biosciences

Junshi Biosciences Reports Key 2019 Financial Results

SHANGHAI, China, March 02, 2020 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. ("the Company," HKEX: 1877), an innovation-driven biopharmaceutical company dedicated to the discovery and...